FDA Approves Inluriyo for Advanced Breast Cancer
Breast Cancer -On September 25, 2025, the U.S. Food and Drug Administration granted approval to imlunestrant (brand name: Inluriyo, from Eli Lilly and Company) for the treatment of adults with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, whose disease progressed after at least one line of endocrine (hormone) therapy.